Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis
Background: Immune checkpoint inhibitors (ICIs) have been an emerging treatment strategy for advanced triple-negative breast cancer (TNBC). Some studies have shown that high expression of programmed death-ligand 1 (PD-L1) can achieve a better response of clinical efficacy. However, the efficacy of I...
Main Authors: | Yingjie Qi, Xin Yan, Chao Wang, Hui Cao, Guangxuan Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1004821/full |
Similar Items
-
Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis
by: Juan Yang, et al.
Published: (2024-02-01) -
Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01) -
PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
by: Yinan Yu, et al.
Published: (2023-06-01) -
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in patients with triple‐negative breast cancer: A systematic review and meta‐analysis
by: Xin Gao, et al.
Published: (2023-12-01) -
Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
by: Ji-Yeon Kim, et al.
Published: (2023-03-01)